But other exploratory analyses showed that higher expression of PD-L1 in tumor tissues, higher expression of vascular endothelial growth factor (VEGF) receptor 2, and higher T-regulatory cells immune phenotype may be associated with longer survival of patients treated by atezolizumab plus bevacizumab (45). This evidence concerns the gene VEGFA and neoplasm.